ADHD Management Guidelines

First-Line Pharmacological Treatment

Stimulant medications, specifically methylphenidate or amphetamines, are the recommended first-line pharmacological treatment for ADHD in both children (≥6 years) and adults, with demonstrated effectiveness in 70-80% of patients 1, 2
The American Academy of Child and Adolescent Psychiatry recommends long-acting formulations over immediate-release preparations due to better medication adherence, lower risk of rebound effects, more consistent symptom control throughout the day, and reduced diversion potential 2, 3
Amphetamine-based stimulants are preferred over methylphenidate in adults based on comparative efficacy studies, though response is idiosyncratic—approximately 40% respond to both, 40% respond to only one 2, 3

The Asian guidelines provide specific formulation availability, including Japan (2022): OROS-MPH (max 54 mg/day), lisdexamfetamine (max 70 mg/day), atomoxetine (max 120 mg/day or 1.8 mg/kg), guanfacine XR (max 6 mg/day) 1, 4, 5

Atomoxetine is the established second-line option for patients who cannot tolerate stimulants, have contraindications, or show inadequate response 2, 3
The American Academy of Child and Adolescent Psychiatry recommends atomoxetine dosing of 0.5 mg/kg/day for pediatric patients (up to 70 kg) and 40 mg/day for pediatric patients (>70 kg) and adults 2

Behavioral interventions are more effective for associated behavioral problems and functioning, while pharmacological interventions are more efficacious for core ADHD symptoms 1
Cognitive Behavioral Therapy (CBT) is the most extensively studied and effective psychotherapy for adult ADHD, focusing on time management, organization, planning, and adaptive behavioral skills 2, 3

For patients with severe symptoms and no contraindication to stimulants, initiate stimulants first, starting with long-acting stimulant (methylphenidate or amphetamine) 1, 2, 3

Regular monitoring must include vital signs, cardiovascular monitoring, growth monitoring in pediatric patients, effectiveness evaluation, side effects monitoring, anxiety symptom tracking, and periodic reevaluation 1, 2, 3

Anxiety does not contraindicate stimulant use but requires careful monitoring, and stimulants can indirectly reduce anxiety related to functional impairment by improving executive function deficits 2, 3
Exercise particular caution when prescribing stimulants to adults with comorbid substance abuse disorder, and long-acting formulations have reduced diversion potential 2, 3

Stimulants have a high potential for abuse and misuse leading to substance use disorder, and common adverse effects include tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, abdominal pain 1
Atomoxetine has a boxed warning for suicidal ideation in children and adolescents, and severe liver injury, and is contraindicated in patients with pheochromocytoma, narrow angle glaucoma, or severe cardiovascular disorders 2, 3